Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies

Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies

Abstract YY-20394, an oral phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, was investigated in a first-in-human study of patients with relapsed or refractory B-cell malignancies. During dose escalation, 25 patients received 20–200 mg of YY-20394 daily. The primary outcome measures were tolera...

Full description

Bibliographic Details
Main Authors: Bo Jiang, Junyuan Qi, Yuqin Song, Zengjun Li, Meifeng Tu, Lingyan Ping, Zongliang Liu, Hanying Bao, Zusheng Xu, Lugui Qiu
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Journal of Hematology & Oncology
Subjects:
Linperlisib
PI3Kδ inhibitor
Dose-limiting toxicity
Non-Hodgkin’s lymphoma
Pharmacokinetics
Online Access:https://doi.org/10.1186/s13045-021-01140-z

Internet

https://doi.org/10.1186/s13045-021-01140-z

Similar Items